Revenue segments as reported by the company.

Product revenue

Service and other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales, general and administrative

Merger-related expenses

Change in fair value of contingent consideration

Amortization of acquired intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pacific Biosciences of California

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

PacBio reports revenue growth and strong demand for Revio

PacBio's Q1 2023 performance showed revenue growth but faced challenges with gross margin and operating expenses. The company's strengths lie in strong cash position, revenue growth expectations, and successful Revio launch. Opportunities include strong demand for Revio, Onso, and potential projects in China.

PacBio achieves record Q2 revenue, focuses on strategic acquisitions

PacBio's Q2 performance was marked by record revenue and strategic acquisitions. The company is focused on driving growth through Revio momentum, long-read technology integration, and reducing backlog. The Apton acquisition is seen as a strategic move to accelerate product development and drive stronger gross margins.

PacBio achieves record revenue growth, faces macroeconomic challenges ahead

PacBio's Q3 performance reflects strong revenue growth and a focus on expanding its customer base. While facing macroeconomic challenges, the company sees opportunities in the long read sequencing market and plans to drive Revio placements and consumable revenue. Challenges include potential impacts on revenue growth and gross margins.

PacBio reports robust 2023 performance, eyes growth through innovation

PacBio's strong financial performance in 2023 sets the stage for continued growth in 2024, with revenue expected to reach $230-250 million. Strategic priorities focus on driving placements, expanding into clinical markets, and improving gross margins. Challenges with sales cycles and consumable yield are being addressed, while opportunities in new technologies and business models offer avenues for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

The gene sequencing company is receiving a $900 million investment from a renowned international conglomerate.

Here's Why Pacific Biosciences of California Stock Popped Today

Here's Why Pacific Biosciences Stock Popped Today

Pacific Biosciences (PACB) delivered earnings and revenue surprises of -102.33% and -0.05%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Pacific Biosciences of California (PACB) Reports Q4 Loss, Misses Revenue Estimates

Shares of Pacific Biosciences (NASDAQ:PACB) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 0.00% over the past year to $0.37, which beat the estimate of $0.32.

Pacific Biosciences: Q4 Earnings Insights

MENLO PARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2020. Reported revenue is consistent with the Company's press release issued on January 11, 2021.

Pacific Biosciences of California, Inc. Announces Fourth Quarter and Fiscal Year 2020 Financial Results

Pacific Biosciences is getting an investment from a holding company.

Why Pacific Biosciences of California Stock Is Soaring Today

SoftBank Group Corp

Shares of Pacific Biosciences of California Inc. shot up 22.3% toward a record in morning trading Wednesday, ahead of the genetic analysis company's fourth-quarter report due out after the closing bell, after the announcement that Japan-based Softbank Group Corp. invested $900 million in the company. The stock has now soared 230.0% over the past three months and skyrocketed 1,051.7% over the past year.

Pacific Biosciences stock rockets ahead of earnings, after Softbank makes $900 million investment

Pacific Biosciences spiked as much as 25% on Wednesday after the company revealed that Softbank plans to invest $900 million into its business. The $900 million investment, which will be in the form of convertible debt, will come from the recently established asset-management arm of SoftBank, SB NorthStar. The investment adds to the unit's roughly 6% current stake Pacific Biosciences.

Pacific Biosciences spikes 25% after announcing a $900 million investment from SoftBank (SFTBY, PACB)

MENLO PARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”), a leading provider of high-quality, long-read sequencing platforms, today announced that SB Management, a subsidiary of Softbank Group Corp., will make an investment of $900 million in convertible senior notes to support the Company's future growth initiatives.

Pacific Biosciences Announces $900 Million Investment from SoftBank to Support Growth Initiatives

SoftBank Group Corp (OTCMKTS: SFTBY) will reportedly invest $900 million into Pacific Biosciences of California Inc (NASDAQ: PACB), according to the Wall Street Journal, which comes on top of around 6% stake in PacBio that Softbank amassed almost a month back, worth over $350 million. Last year, PACB was blocked by U.S. antitrust enforcers from merging with Illumina in a $1.2B deal.

SoftBank To Invest $900M In Pacific Biosciences - WSJ

Pacific Biosciences' (PACB) fourth-quarter results are likely to reflect strength in its Sequel system.

What's in Store for Pacific Biosciences' (PACB) Q4 Earnings?

On Wednesday, February 10, Pacific Biosciences (NASDAQ:PACB) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

Pacific Biosciences Earnings Preview

A new leadership team is betting that it can make long-read genome sequencing more competitive.

Is Pacific Biosciences of California a Ticking Time Bomb for Investors?

MENLO PARK, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its fourth quarter 2020 financial results on Wednesday, February 10, 2021, at 4:30pm Eastern Time.

Pacific Biosciences of California, Inc. Fourth Quarter 2020 Financial Results Call

After a large 13x rise since the March 23 levels of last year, at the current price of around $36 per share we believe Pacific Biosciences of California stock, a biotechnology company that develops gene sequencing systems, has reached its near-term potential. PACB stock has rallied from $3 to $36.

Should You Book Profits In Pacific Biosciences of California After A Massive 13x Rally?

Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of solid prospects.

Why You Should Retain Pacific Biosciences (PACB) Stock Now

Pacific Biosciences' (PACB) preliminary Q420 revenues are expected to improve from Q320.

Pacific Biosciences (PACB) Releases Preliminary Q4 Revenues

New platform expected to make whole genome sequencing significantly more affordable and accessible for use in mainstream medical care New platform expected to make whole genome sequencing significantly more affordable and accessible for use in mainstream medical care

Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform

MENLO PARK, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality, long read sequencing platforms, today announced that the Board of Directors granted non-qualified stock options covering an aggregate of 750,000 shares of Pacific Biosciences common stock and restricted stock units (“RSUs”) covering 335,000 shares of Pacific Biosciences common stock to the Company's recently hired Chief Operating Officer, Mark Van Oene, under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “Inducement Plan”) effective on January 8, 2021.

Pacific Biosciences Grants Equity Incentive Awards to New Employees

MENLO PARK, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (the “Company”) (NASDAQ: PACB), a leading provider of high-quality sequencing platforms, today announced unaudited preliminary revenue of approximately $27 million for its fourth quarter ended December 31, 2020. The Company's full financial results for the fourth quarter and the fiscal year ended December 31, 2020 are not yet available.

Pacific Biosciences of California, Inc. Announces Preliminary Fourth Quarter 2020 Revenue

MENLO PARK, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing solutions, today announced the appointments of Mark Van Oene as Chief Operating Officer and Peter Fromen as Chief Commercial Officer, both effective as of January 8, 2021.

Pacific Biosciences Announces Appointments of Mark Van Oene as Chief Operating Officer and Peter Fromen as Chief Commercial Officer

Seven new Sequel IIe Systems will support expanded generation of high-quality genomes for improving fundamental understanding of biology and aiding biodiversity conservation Seven new Sequel IIe Systems will support expanded generation of high-quality genomes for improving fundamental understanding of biology and aiding biodiversity conservation

Wellcome Sanger Institute Increases Investment in PacBio Long-Read Sequencing to Support Darwin Tree of Life Research Initiative

ABIOMED

Allscripts Healthcare Solutions

Due to the persistence of global manufacturing and supply-chain disruptions and a few other hostile externalities, three stocks are likely to register a dull 2021 performance.

3 MedTech Stocks Up Above 50% That Might Lose Steam in 2021

Investors need to pay close attention to Pacific Biosciences (PACB) stock based on the movements in the options market lately.

Implied Volatility Surging for Pacific Biosciences (PACB) Stock Options

HCA Healthcare

BioCardia Inc.

BioCardia (NASDAQ: BCDA) shares are trading higher. The company said it anticipates data safety monitoring board verbal feedback by the end of Dec. 15 for its pivotal Phase 3 CardiAMP Heart Failure Trial.

News for Pacific Biosciences of California Stock (PACB)